These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 8055461)
1. Application of cancer procoagulant as an early detection tumor marker. Kozwich DL; Kramer LC; Mielicki WP; Fotopoulos SS; Gordon SG Cancer; 1994 Aug; 74(4):1367-76. PubMed ID: 8055461 [TBL] [Abstract][Full Text] [Related]
2. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Gordon SG; Cross BA Cancer Res; 1990 Oct; 50(19):6229-34. PubMed ID: 2169340 [TBL] [Abstract][Full Text] [Related]
3. Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Gordon SG; Benson B Thromb Res; 1989 Nov; 56(3):431-40. PubMed ID: 2617480 [TBL] [Abstract][Full Text] [Related]
4. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients. Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923 [TBL] [Abstract][Full Text] [Related]
5. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383 [TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985 [TBL] [Abstract][Full Text] [Related]
7. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum. Rucińska M; Furman M; Skrzydlewski Z; Zaremba E Acta Biochim Pol; 1997; 44(1):109-12. PubMed ID: 9241361 [TBL] [Abstract][Full Text] [Related]
8. Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. Mielicki WP; Tenderenda M; Rutkowski P; Chojnowski K Cancer Lett; 1999 Nov; 146(1):61-6. PubMed ID: 10656610 [TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma. Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911 [TBL] [Abstract][Full Text] [Related]
10. Elevation of multiple serum markers in patients with stage I ovarian cancer. Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259 [TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
12. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459 [TBL] [Abstract][Full Text] [Related]
13. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Safi F; Kohler I; Röttinger E; Beger H Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278 [TBL] [Abstract][Full Text] [Related]
14. Cancer procoagulant in patients with adenocarcinomas. Kaźmierczak M; Lewandowski K; Wojtukiewicz MZ; Turowiecka Z; Kołacz E; Lojko A; Skrzydlewska E; Zawilska K; Komarnicki M Blood Coagul Fibrinolysis; 2005 Nov; 16(8):543-7. PubMed ID: 16269926 [TBL] [Abstract][Full Text] [Related]
15. Cancer procoagulant in serum of rats during development of experimental epithelioma. Mielicki W; Wierzbicki R Int J Cancer; 1990 Jan; 45(1):125-6. PubMed ID: 2298496 [TBL] [Abstract][Full Text] [Related]
16. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289 [TBL] [Abstract][Full Text] [Related]
17. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas. Liu C; Ma H; Qu L; Wu J; Meng L; Shou C Hepatogastroenterology; 2012 Oct; 59(119):2222-7. PubMed ID: 22440249 [TBL] [Abstract][Full Text] [Related]
18. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Nilsson O; Johansson C; Glimelius B; Persson B; Nørgaard-Pedersen B; Andrén-Sandberg A; Lindholm L Br J Cancer; 1992 Feb; 65(2):215-21. PubMed ID: 1739620 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Comparison with CEA and CA-125. Verlooy H; Devos P; Janssens J; Mortelmans L; Gerits M; Bonte J; De Roo M Gynecol Obstet Invest; 1991; 32(1):55-8. PubMed ID: 1765320 [TBL] [Abstract][Full Text] [Related]
20. An expert system approach for the objective interpretation of serum tumour marker levels. Stajić S; Novaković R; Bosnjaković V Nucl Med Commun; 1994 Apr; 15(4):298-304. PubMed ID: 8072745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]